| Literature DB >> 30275970 |
Jin Hyun Lee1,2.
Abstract
BACKGROUND: Injectable hydrogels have been extensively researched for the use as scaffolds or as carriers of therapeutic agents such as drugs, cells, proteins, and bioactive molecules in the treatment of diseases and cancers and the repair and regeneration of tissues. It is because they have the injectability with minimal invasiveness and usability for irregularly shaped sites, in addition to typical advantages of conventional hydrogels such as biocompatibility, permeability to oxygen and nutrient, properties similar to the characteristics of the native extracellular matrix, and porous structure allowing therapeutic agents to be loaded. MAIN BODY: In this article, recent studies of injectable hydrogel systems applicable for therapeutic agent delivery, disease/cancer therapy, and tissue engineering have reviewed in terms of the various factors physically and chemically contributing to sol-gel transition via which gels have been formed. The various factors are as follows: several different non-covalent interactions resulting in physical crosslinking (the electrostatic interactions (e.g., the ionic and hydrogen bonds), hydrophobic interactions, π-interactions, and van der Waals forces), in-situ chemical reactions inducing chemical crosslinking (the Diels Alder click reactions, Michael reactions, Schiff base reactions, or enzyme-or photo-mediated reactions), and external stimuli (temperatures, pHs, lights, electric/magnetic fields, ultrasounds, or biomolecular species (e.g., enzyme)). Finally, their applications with accompanying therapeutic agents and notable properties used were reviewed as well.Entities:
Keywords: Crosslinking reaction; Disease and cancer therapy; Injectable hydrogels; Therapeutic agent delivery; Tissue repair and regeneration
Year: 2018 PMID: 30275970 PMCID: PMC6158836 DOI: 10.1186/s40824-018-0138-6
Source DB: PubMed Journal: Biomater Res ISSN: 1226-4601
Fig. 1The schematic illustration of the formation procedure of injectable hydrogels containing therapeutic agents through the sol-gel transition induced by physical or chemical crosslinking reactions with or without external stimuli after injection (above). The diagrams of the crosslinking mechanisms (chemical and physical crosslinking) and external stimuli contributing to the sol-gel transition (below)
The injectable hydrogel systems and their crosslinking reactions/interactions and applications
| Injectable Hydrogel Systems | Crosslinking Reactions/Interactions | Applications (therapeutic agents) | Notes | References |
|---|---|---|---|---|
| Agar | ||||
| Agar/MBP | PC, HB/ | Delivery of TD (DOX), chemotherapy for colon cancer, photothermal treatment by MBP | Temperature-sensitive release, temperature changed by MBP (a photoabsorbent) | [ |
| Alginate | ||||
| Alginate-Ca | PC, EI/ | Delivery of TD (MX) and TPs (SDF-1α and pDNA), breast cancer therapy | Self-healing, the release and therapeutic efficacy regulated by pulsatile ultrasound | [ |
| OAlg/CMCS with GMs-TH | CC, SBR/ | Bacterial infection therapy | Antibacterial and biodegradable properties | [ |
| Chitosan | ||||
| Chitosan/gelatin/polydopamine | PC, EI/ MR, SBR, | Parkinson’s disease therapy, TD delivery (MT) | Mechanical strength improved via EI | [ |
| Chitosan/gelatin/NDs | PC, EI, HB, VDWF/HB, DDI, HP | Scaffold for TE (embedded cell: VEGF) | Thermosensitive gelation, mechanical features improved by NDs, sustained release | [ |
| Chitosan-polyaniline/oxidized dextran | CC, SBR/ | Delivery of TDs (Amoxicillin and ibuprofen) | pH- and electric field- responsive, antibacterial activity | [ |
| CEC/OSA | CC, MR/ | TAD | Self-assembling, self-healing | [ |
| GC/poly(EO-co-Gly)-CHO | CC, SBR/ | Scaffold for TE (embedded cell: chondrocyte), cartilage repair | Mechanical properties and morphology controlled by poly(EO-co-Gly)-CHO | [ |
| Chondroitin Sulfate (ChS) | ||||
| Pluronic F127-ChS/PEG | CC, DACR/ | Scaffold for TE (embedded cell: BMP-4), bone defect repair | Gelation of Pluronic F127-ChS at 37 oC, dual crosslinked Pluronic F127-ChS/PEG hydrogels | [ |
| Collagen | ||||
| Collagen/Au | PC, EI/ | PTT, PDT, TAD (TMPyP), breast cancer therapy | Shear-thinning, self-healing, antitumor efficacy affected by light irradiation | [ |
| Collagen | PC, EI/ | Scaffold for TE (embedded cell: osteoblast (OB)), bone repair | Successful bone tissue regeneration by OB and LIPUS | [ |
| Dextrin | ||||
| CD/PEG-phospholipid/Fe3O4 | PC, HI/ | Hyperthermia cancer therapy, chemotherapy for preventing breast cancer recurrence, delivery of TDs (PTX, DOX) | PTX and DOX Released by ACMF induced heat | [ |
| Gelatin | ||||
| Gelatin MPs | PC, EI/ | Scaffold for TE (embedded TPs: VEGF and BMP2) | Release controlled by hydrogel degradation induced by CLSPA collagenase | [ |
| Gelatin-tetrazine fg/Gelatin- norbornene fg | CC, DACR/ | Scaffold for TE | Cell-compatible and enzymatically degradable properties | [ |
| Hyaluronic acid (HA) | ||||
| HA-CD/ HA-AD, and HA-CD-MA/HA-AD-MA | PC, HGI, CC/ | Delivery of TP (EPC), vascular regeneration | Shear-thinning, self-healing | [ |
| HA-HMDA-cytosine/HA-HMDA-guanosine | PC, HB/ | Delivery of TP (BSA), scaffold for TE | pH-sensitive and self-healing, gelation only at pH 6-8 | [ |
| HAMC | PC, EI, HB/ | Delivery of TPs (RSCs, NSCs), retina and brain tissue therapy, scaffold for TE | Biodegradable and light-sensitive, HAMC-CD44 interaction | [ |
| HA-Heparin (HA-HP) | CC, PIC/ | Delivery of TP (AFS), wound healing | Crosslinking by UV light | [ |
| HA-Tyr | CC, EMCR, OCR/ | Scaffold for TE (embedded cell: hESC) | Highest hESC proliferation at HA-Tyr hydrogels with modulus of 350 Pa | [ |
| Peptide/protein | ||||
| P1 | PC, PI, HP/ | Delivery of TDs (vitamin B12 and vancomycin, an antibiotic) | Thixotropic behavior at physiological condition | [ |
| FGd/Ag | PC, PI/ | Antimicrobial treatment with Ag | Mechanical stability for six months, high antimicrobial activity | [ |
| PA | PC, HI, HB, EI/ | Chemotherapy, delivery of TD (DOX) | PA concentration-dependent release behavior | [ |
| Peptide/catalase/glucose oxidase | PC, EI/ | Diabetic therapy, delivery of TP (insulin) | pH- and glucose-sensitive, self-assembling | [ |
| Multi-domain peptides (MDPs) nanofiber/liposome NPs | PS, HB, HI/ | Delivery of TPs (EGF, PlGF-1, MCP-1), Scaffold for TE | Release regulated via the hydrogel degradation by enzyme-mediation and the physical gelation by self-assembly | [ |
| Protein and Protein-GOX-CAT (PGT) | CC, EMCR/ | Scaffold for TE | Reversible self-healing, enzyme (glucose) mediated crosslinking by dynamic covalent interaction, 100% recovery PGT | [ |
| PCL | ||||
| PEG-PCL-PEG | PC, HI/ | Chemotherapy including diabetic treatment, delivery of TP (insulin) | Sol-gel transition at 37 oC, lower viscosity than Pluronic®, Fickian release | [ |
| PEG | ||||
| Polyamine-PEG-polyamine | PC, CC, EI, HB, PI/ | Delivery of TPs (insulin, BSA, glucose, avidin, neutravidin, or IL-12) | Self-assembling at 30 oC | [ |
| PLga-PEG-PLga -chol fg/ PLga-CD fg | PC, HGI/ | Scaffold for TE | Self-healing, self-assembling, properties regulated by the ratio of CD/Chol, high storage modulus | [ |
| PCLA-PEG-PCLA/heparin | PC, HI, CC, MR/EI | Delivery of TP (lysozyme), immunotherapy | Thermosensitive gelation at BT, sustained release | [ |
| PEG- aryl thiol fg/PEG-maleimide fg (or heparin-maleimide fg) | CC, MR/RLI | Delivery of TPs (FGF-2, cytokines, and immunomodulatory agents) | Light-and reducing environment- sensitive release | [ |
| PEG/TMVCyss and PEG/wt-TMV | CC, MR and PC/ | Scaffold for TE | TMV with multi-functionality, storage moduli improved by adding TMVCyss. No effect of wt-TMV on storage moduli | [ |
| PEG/PPLL | CC, SBR/ | Delivery of TDs (ME and 5FC), colon cancer therapy | Degradation and release controlled by pHs | [ |
| Polyoxamine | ||||
| Polyoxamine-maleimide fg/ Polyoxamine-furyl fg | PC, CC, HI, DACR/ | Delivery of TP (bevacizumab, an antibody), colon, lung, and breast cancer therapy | Physical and chemical crosslinking, triphasic release controlled by two polyoxamines | [ |
| PVA | ||||
| PVA-Tyr and PVA-Tyr-sericin-gelatin (PVA-SG) | CC, PIC/ | Scaffold for TE (embedded TP: Schwann) | Crosslinking by visible light, PVA-Tyr: no cell adhesion, PVA-SG: cell adhesion | [ |
| PNIPAAm | ||||
| PNIPAAm/CNC | PC, VDWF, HB/ | Delivery of TD (MT), wound dressing | Volume transition at 36-39 oC, Mechanical strength increased by CNC | [ |
Abbreviations: ACMF Alternating current magnetic field, AD Adamantine, AFS Amniotic fluid-derived stem, BMP2 bone morphogenetic protein 2, BMP-4 Bone morphogenetic protein 4, BSA Bovine serum albumin, BT Body temperature, CAT Catalase, CC Chemical crosslinking, CD Cyclodextrin, CEC N-Carboxyethyl chitosan, Chol Cholesterol, CLSPA collagenase Chromatographically purified collagenase, CMCS carboxymethyl chitosan, CNC Cellulose nanocrystal, DACR Diels Alder click reaction, DDI dipole-dipole interaction, pDNA plasmid DNA, Dox doxorubicin, EGF Epidermal growth factor, EI Electrostatic interaction, EMCR Enzyme-mediated crosslinking reaction, EPC Endothelial progenitor cell, FGF-2 Fibroblast growth factor, fg functional group, 5FU 5-fluorouracil, GC glycol chitosan, G 20-deoxy-20-fluoroguanosine, GMs Gelatin microspheres, GOX Glucose oxidase, HA Hyaluronic acid, HAMC Hyaluronic acid-methylcellulose, HB Hydrogen bonding, hESCs Human embryonic stem cells, HGI Host-gest interactions, HI Hydrophobic interaction, HMDA Hexamethylenediamine, IL-12 Interleukin-12, LIPUS Low-intensity pulsed and ultrasound, MA Methyl acrylate, MBP MoS2/Bi2S3-PEG, MCP-1 monocyte chemoattractant protein-1, ME Metformin, MGH Magnetic gellan gum hydrogel, MPs microparticles, MR Michael reaction, MT Metronidazole, MX Mitoxantrone, NDs Nanodiamonds, NPs Nanoparticles, NSCs Neural stem and progenitor cells, OAlg Oxidized alginate, OCR Oxidative coupling reaction, OSA Oxidized sodium alginate, P1 boc-AUDA-Phe-COOH (AUDA 11-aminoundecanoic acid, Phe L-phenylalanine), PA Peptide amphiphile, PC Physical crosslinking, PCL Polycaprolactone, PCLA Poly-(ε-caprolactone-co-lactide), PDT Photodynamic therapy, PEG Polyethylene glycol, PI π-Interaction, PIC Photo-initiated crosslinking, PLga Poly(L-glutamic acid), PlGF-1 Placental growth factor-1, PNIPAAm Poly(N-isopropylacrylamide), PPLL PEG-b-poly(L-lysine), Poly(EO-co-Gly)-CHO Poly(ethylene oxide-co-glycidol)-CHO, PTT Photothermal therapy, PTX Paclitaxel, PVA Poly(vinyl alcohol), PVA-SG PVA-tyramine-sericin-gelatin, RLI Receptor–ligand interaction, RSCs Retinal stem cells, SBR Schiff base reaction, SDF-1α stromal cell-derived factor 1α, TAD Therapeutic agent delivery, TDs Therapeutic drugs, TE Tissue engineering, TH Tetracycline hydrochloride, TPs Therapeutic proteins, TMPyP meso-tetra(N-methyl-4-pyridyl) porphine tetrachloride (a photosensitive drug), TMV Tobacco mosaic virus, wt-TMV Wildtype TMV, TMVs Cysteine-containing TMV mutants, Tyr Tyramine, VDWF van der Waals force, and VEGF Vascular endothelial growth factors